Is Metropolis Healt overvalued or undervalued?

As of 2 September 2025, the valuation grade for Metropolis Health has moved from expensive to very expensive. This indicates a significant shift in the company's valuation outlook, suggesting that it is currently overvalued. The company exhibits a PE ratio of 74.06, an EV to EBITDA of 36.15, and a PEG ratio of 7.56, all of which are considerably high compared to industry standards.
When compared to peers, Metropolis Health's valuation metrics are notably elevated. For instance, Max Healthcare has a PE ratio of 93.55, while Apollo Hospitals is at 70.09, both of which are lower than Metropolis Health's. Furthermore, the company's return over the past year stands at 3.24%, outperforming the Sensex's decline of 2.91%, yet this does not mitigate the concerns regarding its high valuation. Overall, Metropolis Health appears to be overvalued in the current market environment.